Moderna, Inc. (MRNA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Moderna, Inc. (MRNA) Healthcare & Pipeline Overview

Moderna, Inc. pioneers mRNA therapeutics and vaccines, targeting infectious diseases, oncology, and rare conditions. With strategic alliances and a diverse pipeline, the company navigates a competitive landscape, leveraging its mRNA platform for innovation in the biotechnology sector, despite current negative profitability.

What Is the Investment Thesis for MRNA?

Moderna's investment thesis hinges on its mRNA technology platform and its potential to revolutionize vaccine development and therapeutics. The company's success with its COVID-19 vaccine has validated its technology, but its future growth depends on diversifying its pipeline and achieving commercial success in other therapeutic areas. Key value drivers include the development and approval of new mRNA vaccines and therapeutics, particularly in areas like RSV, flu, and cancer. Upcoming data readouts from clinical trials and potential regulatory approvals are key catalysts. However, the company's negative profit margin of -143.6% and gross margin of -13.9% raise concerns about its financial sustainability. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's beta of 1.34 suggests higher volatility compared to the market.

Based on FMP financials and quantitative analysis

MRNA Key Highlights

Market capitalization of $21.43 billion reflects investor valuation of Moderna's mRNA platform and future potential.

• Negative profit margin of -143.6% indicates the company is currently not profitable, largely due to high R&D expenses and fluctuating vaccine demand.
• Gross margin of -13.9% suggests challenges in controlling production costs and pricing pressures.
• Strategic alliances with AstraZeneca, Merck, and Vertex provide access to resources and expertise, de-risking development programs.
• Diverse pipeline targeting infectious diseases, immuno-oncology, and rare diseases offers multiple avenues for growth and revenue generation.

Who Are MRNA's Competitors?

MRNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MRNA's Key Strengths?

Pioneering mRNA technology platform.

• Rapid vaccine development capabilities.
• Strategic alliances with major pharmaceutical companies.
• Strong intellectual property portfolio.

What Are MRNA's Weaknesses?

Negative profit margin and gross margin.

• Reliance on vaccine sales.
• Limited track record in non-vaccine therapeutics.
• High R&D expenses.

What Could Drive MRNA Stock Higher?

Clinical trial data readouts for RSV and flu vaccines in Q3 2026.

• Potential regulatory approvals for RSV vaccine in the US and Europe by Q4 2026.
• Expansion of mRNA platform into new therapeutic areas, including cancer and autoimmune diseases.
• Strategic partnerships and collaborations to accelerate drug development and commercialization.

What Are the Key Risks for MRNA?

Negative return on equity (-36.7%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $2.5M recently.
• Clinical trial failures for key pipeline candidates.
• Regulatory delays or rejection of product approvals.
• Competition from established pharmaceutical companies and other biotechnology firms.
• Fluctuations in vaccine demand and pricing pressures.
• Intellectual property disputes and challenges to patent protection.

What Are the Growth Opportunities for MRNA?

• Expansion into RSV Vaccine Market: Moderna is developing an mRNA-based RSV vaccine targeting older adults. Successful development and commercialization of its RSV vaccine could generate significant revenue for Moderna, providing a strong foothold in the respiratory vaccine market. The timeline for potential approval and launch is estimated within the next 1-2 years, pending clinical trial results and regulatory review.
• Advancement of Personalized Cancer Vaccines: Moderna is pioneering personalized cancer vaccines based on mRNA technology. These vaccines are designed to target specific mutations in a patient's tumor, stimulating an immune response against cancer cells. The personalized cancer vaccine market is expected to grow rapidly, driven by advancements in genomics and immunotherapy. Success in this area would position Moderna as a leader in personalized cancer treatment, with potential for high revenue and significant impact on patient outcomes. Clinical trials are ongoing, with potential for initial data readouts in the next 2-3 years.
• Development of mRNA-Based Flu Vaccines: Moderna is developing mRNA-based flu vaccines that offer the potential for improved efficacy and faster development compared to traditional flu vaccines. The flu vaccine market is a large and established market, with annual sales in the billions of dollars. Moderna's mRNA flu vaccine could capture a significant share of this market by offering superior protection and faster response to emerging flu strains. Clinical trials are underway, with potential for commercial launch within the next 3-5 years.
• Strategic Partnerships and Collaborations: Moderna's strategic alliances with companies like AstraZeneca, Merck, and Vertex provide access to resources, expertise, and funding, accelerating the development and commercialization of its mRNA therapeutics and vaccines. These partnerships also de-risk development programs and expand Moderna's reach into new therapeutic areas. Ongoing collaborations with government and non-profit organizations, such as DARPA and The Bill & Melinda Gates Foundation, support research and development efforts in areas of public health concern. These partnerships are ongoing and expected to continue driving innovation and growth.
• Expansion into New Therapeutic Areas: Moderna is expanding its pipeline beyond vaccines into new therapeutic areas, including cardiovascular diseases, autoimmune diseases, and rare diseases. This diversification strategy reduces the company's reliance on vaccines and opens up new opportunities for growth. The market for mRNA therapeutics in these areas is significant, with potential for high revenue and significant impact on patient outcomes. Moderna's mRNA platform provides a competitive advantage in developing novel therapies for these diseases. The timeline for potential product launches varies depending on the specific therapeutic area and development stage.

What Are MRNA's Competitive Advantages?

• Proprietary mRNA Technology Platform: Moderna's mRNA platform enables rapid development and manufacturing of new vaccines and therapeutics, providing a significant competitive advantage.
• Extensive Intellectual Property Portfolio: Moderna has a large portfolio of patents protecting its mRNA technology and products, creating barriers to entry for competitors.
• Strategic Alliances and Collaborations: Moderna's partnerships with leading pharmaceutical companies and research institutions provide access to resources, expertise, and funding.
• First-Mover Advantage: Moderna was one of the first companies to develop and commercialize mRNA vaccines, giving it a head start in the market.

What Does MRNA Do?

Moderna, Inc., founded in 2010 and headquartered in Cambridge, Massachusetts, is a biotechnology company revolutionizing medicine through messenger RNA (mRNA) technology. Initially named Moderna Therapeutics, the company changed its name in August 2018 to reflect its expanding focus. Moderna's core business revolves around discovering, developing, and commercializing mRNA therapeutics and vaccines. Its diverse pipeline addresses a wide range of diseases, including infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna's respiratory vaccine portfolio includes vaccines for COVID-19, flu, respiratory syncytial virus (RSV), Endemic HCoV, and hMPV+PIV3. The company also develops latent vaccines targeting cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV). Public health vaccines for Zika and Nipah are also part of their portfolio. Beyond vaccines, Moderna is developing systemic secreted and cell surface therapeutics, cancer vaccines (personalized cancer, KRAS, checkpoint), intratumoral immuno-oncology products, and localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. Moderna has established strategic alliances with companies like AstraZeneca PLC, Merck & Co., Inc., and Vertex Pharmaceuticals Incorporated, as well as collaborations with government and non-profit organizations like the Defense Advanced Research Projects Agency (DARPA) and The Bill & Melinda Gates Foundation. These partnerships support research, development, and commercialization efforts across its therapeutic areas.

What Products and Services Does MRNA Offer?

• Develop and commercialize messenger RNA (mRNA) therapeutics and vaccines.
• Target infectious diseases like COVID-19, flu, and RSV with mRNA vaccines.
• Create personalized cancer vaccines tailored to individual patient tumors.
• Develop therapies for rare diseases, cardiovascular diseases, and autoimmune diseases.
• Utilize strategic alliances with pharmaceutical companies and research institutions.
• Pioneer mRNA technology for rapid vaccine development and manufacturing.
• Conduct clinical trials to evaluate the safety and efficacy of mRNA therapeutics.

How Does MRNA Make Money?

• Develop and patent mRNA-based therapeutics and vaccines.
• Generate revenue through product sales, licensing agreements, and collaborations.
• Invest heavily in research and development to expand its pipeline.
• Partner with pharmaceutical companies for manufacturing and distribution.

What Industry Does MRNA Operate In?

Moderna operates in the rapidly evolving biotechnology industry, characterized by intense competition, high R&D costs, and stringent regulatory requirements. The market for mRNA therapeutics and vaccines is projected to grow significantly, driven by advancements in technology and increasing demand for personalized medicine. Moderna competes with established pharmaceutical companies and other biotechnology firms, including RVMD: Revolution Medicines, Inc., BBIO: BridgeBio Pharma, Inc., JAZZ: Jazz Pharmaceuticals plc, EXEL: Exelixis, Inc., and MDGL: Madrigal Pharmaceuticals, Inc. The company's mRNA platform provides a competitive advantage, enabling rapid development and manufacturing of new vaccines and therapeutics. However, Moderna faces challenges in scaling up production, navigating regulatory hurdles, and maintaining its competitive edge.

Who Are MRNA's Key Customers?

• Governments purchasing vaccines for national immunization programs.
• Healthcare providers administering vaccines and therapeutics to patients.
• Pharmaceutical companies partnering for drug development and commercialization.
• Patients receiving mRNA-based vaccines and therapeutics.

Company Profile

Moderna, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Stéphane Bancel. MRNA has traded publicly since 2018.

Return on equity for Moderna, Inc. stands at -36.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -27.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.5%, the inverse of the P/E and a quick read on earnings relative to price.

MRNA Valuation & Market Position

Analyst price targets span from $25.00 to $245.00, with a consensus of $115.70. At the current price of $136.62, that implies roughly 15% downside from the consensus target. Relative to its peer group, MRNA's quantitative score of 30/100 is below the peer average of 73/100.

Quarterly Financial Performance: Moderna, Inc.

Revenue for Moderna, Inc. came in at $145.0M during Q2 FY2026, a 62.7% contraction versus the preceding quarter. The company recorded a net loss of $782.0M, with diluted EPS of $-1.97. Revenue has contracted over three consecutive quarters, which investors in this unknown Healthcare stock should monitor closely. Across the four most recent quarters, MRNA averaged $-2.00 in diluted EPS.

Moderna, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 8.03 places it in the safe zone, indicating low near-term bankruptcy risk.

Moderna, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 33.4% above estimates on average.

Over the past six months, Moderna, Inc. insiders filed 15 SEC Form 4 transactions — 10 sales and 5 purchases. On net that is roughly 17K shares disposed (about $2.5M), a signal worth weighing alongside the fundamentals.

MRNA Financials

MRNA Latest News

MRNA Analyst Consensus

MRNA MoonshotScore

Latest Moderna, Inc. Analysis

Related Investment Themes

MRNA Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources